CORCEPT THERAPEUTICS INC (CORT) FY2026 YTD Q2 P&L / Income Statement

CORCEPT THERAPEUTICS INC (CORT) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Product revenue, net

421,050,000 US dollars

Cost of sales

6,944,000 US dollars

Gross profit (calculated)

414,106,000 US dollars

Operating expenses (calculated)

422,407,000 US dollars

Income (loss) from operations

negative 8,301,000 US dollars

Interest and other income

9,517,000 US dollars

Income before income taxes

1,216,000 US dollars

Income tax (expense) benefit

negative 10,010,000 US dollars

Net income

11,226,000 US dollars

Hypercortisolism Products

373,486,000 US dollars

Lifyorli

47,564,000 US dollars

Research and development

120,155,000 US dollars

Selling, general and administrative

302,252,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.